Japan · Delayed Price · Currency is JPY Fuji Pharma Statistics
Total Valuation
Fuji Pharma has a market cap or net worth of JPY 48.19 billion. The enterprise value is 67.14 billion.
| Market Cap | 48.19B |
| Enterprise Value | 67.14B |
Important Dates
The last earnings date was Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | Sep 29, 2026 |
Share Statistics
Fuji Pharma has 26.12 million shares outstanding. The number of shares has increased by 2.77% in one year.
| Current Share Class | 26.12M |
| Shares Outstanding | 26.12M |
| Shares Change (YoY) | +2.77% |
| Shares Change (QoQ) | +3.85% |
| Owned by Insiders (%) | 37.23% |
| Owned by Institutions (%) | 15.46% |
| Float | 14.40M |
Valuation Ratios
The trailing PE ratio is 15.45 and the forward PE ratio is 10.40.
| PE Ratio | 15.45 |
| Forward PE | 10.40 |
| PS Ratio | 0.80 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | 8.75 |
| P/OCF Ratio | 6.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.99, with an EV/FCF ratio of 12.19.
| EV / Earnings | 22.45 |
| EV / Sales | 1.12 |
| EV / EBITDA | 5.99 |
| EV / EBIT | 9.56 |
| EV / FCF | 12.19 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.66 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 2.58 |
| Debt / FCF | 5.25 |
| Interest Coverage | 18.24 |
Financial Efficiency
Return on equity (ROE) is 6.14% and return on invested capital (ROIC) is 8.73%.
| Return on Equity (ROE) | 6.14% |
| Return on Assets (ROA) | 4.57% |
| Return on Invested Capital (ROIC) | 8.73% |
| Return on Capital Employed (ROCE) | 10.73% |
| Weighted Average Cost of Capital (WACC) | 4.22% |
| Revenue Per Employee | 34.15M |
| Profits Per Employee | 1.70M |
| Employee Count | 1,760 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.54 |
Taxes
In the past 12 months, Fuji Pharma has paid 423.00 million in taxes.
| Income Tax | 423.00M |
| Effective Tax Rate | 12.39% |
Stock Price Statistics
The stock price has increased by +25.51% in the last 52 weeks. The beta is 0.33, so Fuji Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +25.51% |
| 50-Day Moving Average | 1,957.02 |
| 200-Day Moving Average | 2,042.95 |
| Relative Strength Index (RSI) | 44.81 |
| Average Volume (20 Days) | 109,265 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Fuji Pharma had revenue of JPY 60.11 billion and earned 2.99 billion in profits. Earnings per share was 119.39.
| Revenue | 60.11B |
| Gross Profit | 23.68B |
| Operating Income | 7.02B |
| Pretax Income | 3.41B |
| Net Income | 2.99B |
| EBITDA | 11.20B |
| EBIT | 7.02B |
| Earnings Per Share (EPS) | 119.39 |
Balance Sheet
The company has 9.95 billion in cash and 28.89 billion in debt, with a net cash position of -18.94 billion or -725.20 per share.
| Cash & Cash Equivalents | 9.95B |
| Total Debt | 28.89B |
| Net Cash | -18.94B |
| Net Cash Per Share | -725.20 |
| Equity (Book Value) | 51.88B |
| Book Value Per Share | 1,986.04 |
| Working Capital | 21.72B |
Cash Flow
In the last 12 months, operating cash flow was 7.73 billion and capital expenditures -2.22 billion, giving a free cash flow of 5.51 billion.
| Operating Cash Flow | 7.73B |
| Capital Expenditures | -2.22B |
| Depreciation & Amortization | 4.18B |
| Net Borrowing | -2.18B |
| Free Cash Flow | 5.51B |
| FCF Per Share | 210.87 |
Margins
Gross margin is 39.39%, with operating and profit margins of 11.68% and 4.97%.
| Gross Margin | 39.39% |
| Operating Margin | 11.68% |
| Pretax Margin | 5.68% |
| Profit Margin | 4.97% |
| EBITDA Margin | 18.63% |
| EBIT Margin | 11.68% |
| FCF Margin | 9.61% |
Dividends & Yields
This stock pays an annual dividend of 49.00, which amounts to a dividend yield of 2.66%.
| Dividend Per Share | 49.00 |
| Dividend Yield | 2.66% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 4 |
| Payout Ratio | n/a |
| Buyback Yield | -2.77% |
| Shareholder Yield | -0.11% |
| Earnings Yield | 6.20% |
| FCF Yield | 11.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Fuji Pharma is 3,000.00, which is 62.60% higher than the current price. The consensus rating is "Buy".
| Price Target | 3,000.00 |
| Price Target Difference | 62.60% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 12.00% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Fuji Pharma has an Altman Z-Score of 2.24 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 7 |